# Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

> **NCT01876953** · PHASE1,PHASE2 · TERMINATED · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** idarubicin
- **DRUG:** dasatinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01876953
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09-13
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-04-25
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Due to the budget issues, the study discontinued at Phase II.
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876953, "Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01876953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*